Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
"A006" is a code name that refers to several distinct entities within the provided context. One prominent entity is an Albuterol dry powder inhaler (DPI) formulation, developed for the treatment of asthma and bronchospasm. This formulation has undergone clinical studies to evaluate its efficacy, dose-ranging, and safety profiles. Another distinct entity is OIC-A006, an osteogenic inductive compound belonging to the amine family. OIC-A006 has been shown to promote osteogenesis both in vitro and in vivo by stimulating bone marrow mesenchymal stem cells and their expression of markers like alkaline phosphatase, osteopontin, osteocalcin, and core-binding factor a1, with potential applications in bone regeneration and healing of large segmental defects. Additionally, "A006" also refers to a Listeria bacteriophage, which is utilized for the rapid bioluminescence-based detection and differentiation of viable Listeria cells, integrating into bacterial tRNA genes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on A006.